Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 15/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.41 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8594103 | 0.81 | CA2 (0.57) | PTGS2PTGS1 | |
| SCHEMBL6609079 | 0.81 | SMN1; SMN2 (0.47) | PTGS2 | |
| SCHEMBL10922491 | 0.78 | PTGS2 (0.42) | PTGS2PTGS1 | |
| SCHEMBL9694039 | 0.77 | NPC1 (0.44) | — | |
| SCHEMBL6608198 | 0.77 | KEAP1 (0.53) | PTGS2 | |
| SCHEMBL67548 | 0.74 | ACHE (0.38) | — | |
| SCHEMBL3741612 | 0.74 | ALDH1A1 (0.64) | — | |
| SCHEMBL6607415 | 0.74 | SCN9A (0.51) | — | |
| SCHEMBL25097 | 0.73 | ALDH1A1 (0.45) | — | |
| SCHEMBL769959 | 0.73 | ALDH1A1 (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060252751-A1 | 3-Aminopyrrolidine derivaties as modulators of chemokine receptors | INCYTE HOLDINGS CORPORATION | 2006-11-09 | — | — | US | claimed |
| US-6342510-B1 | ANTIINFLAMMATORY AGENTS AND ENZYME INHIBITORS | G. D. SEARLE & CO. | 2002-01-29 | — | — | US | claimed |
| EP-2231558-B1 | 3,4-SUBSTITUTED PYRROLIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME (US) | 2014-09-03 | — | — | EP | disclosed |
| US-8354545-B2 | 3,4-substituted pyrrolidine beta-secretase inhibitors for the treatment of alzheimer's disease | Merck, Sharp & Dohme, Corp. (US) | 2013-01-15 | — | — | US | disclosed |
| US-7834021-B2 | 3-aminopyrrolidine derivatives as modulators of chemokine receptors | INCYTE CORPORATION (US) | 2010-11-16 | — | — | US | disclosed |
| US-20100280009-A1 | 3,4-SUBSTITUTED PYRROLIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME LLC | 2010-11-04 | — | — | US | disclosed |
| EP-2231558-A1 | 3,4-SUBSTITUTED PYRROLIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | Merck Sharp & Dohme Corp. (US) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009078932-A1 | 3,4-SUBSTITUTED PYRROLIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK & CO., INC. (US) | 2009-06-25 | — | — | WO | disclosed |
| US-20060252751-A1 | 3-Aminopyrrolidine derivaties as modulators of chemokine receptors | INCYTE HOLDINGS CORPORATION | 2006-11-09 | — | — | US | disclosed |
| CN-1442139-A | Medicinal composition for treating inflammation | SEARLE & CO (US) | 2003-09-17 | — | — | CN | disclosed |
| CN-1107058-C | Substituted isoxazoles for the treatment of disorders | SEARLE & CO (US) | 2003-04-30 | — | — | CN | disclosed |
| US-6342510-B1 | ANTIINFLAMMATORY AGENTS AND ENZYME INHIBITORS | G. D. SEARLE & CO. | 2002-01-29 | — | — | US | disclosed |
| CN-1181075-A | Substituted isoxazoles for the treatment of disorders | SEARLE & CO (US) | 1998-05-06 | — | — | CN | disclosed |
| EP-0783486-A1 | NOVEL PROSTAGLANDIN SYNTHASE INHIBITORS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-07-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252751-A1 | 3-Aminopyrrolidine derivaties as modulators of chemokine receptors | CCR2, CXCR3, CCR5 | PTGS2 1816/4885PTGS1 681/4885ENPP2 718/4885 |
| US-20100280009-A1 | 3,4-SUBSTITUTED PYRROLIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | BACE1, BACE2, PSEN1 | PTGS2 1384/4885PTGS1 710/4885ENPP2 1356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.